[go: up one dir, main page]

AU6465798A - Diagnosing neurologic disorders - Google Patents

Diagnosing neurologic disorders

Info

Publication number
AU6465798A
AU6465798A AU64657/98A AU6465798A AU6465798A AU 6465798 A AU6465798 A AU 6465798A AU 64657/98 A AU64657/98 A AU 64657/98A AU 6465798 A AU6465798 A AU 6465798A AU 6465798 A AU6465798 A AU 6465798A
Authority
AU
Australia
Prior art keywords
neurologic disorders
diagnosing
diagnosing neurologic
disorders
neurologic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64657/98A
Inventor
Michael G. Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROMARK
Original Assignee
NEUROMARK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROMARK filed Critical NEUROMARK
Publication of AU6465798A publication Critical patent/AU6465798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU64657/98A 1997-03-14 1998-03-13 Diagnosing neurologic disorders Abandoned AU6465798A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3658697P 1997-03-14 1997-03-14
US60036586 1997-03-14
US6140297P 1997-09-30 1997-09-30
US60061402 1997-09-30
US3793398A 1998-03-10 1998-03-10
US09037933 1998-03-10
PCT/US1998/005045 WO1998040748A1 (en) 1997-03-14 1998-03-13 Diagnosing neurologic disorders

Publications (1)

Publication Number Publication Date
AU6465798A true AU6465798A (en) 1998-09-29

Family

ID=27365060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64657/98A Abandoned AU6465798A (en) 1997-03-14 1998-03-13 Diagnosing neurologic disorders

Country Status (2)

Country Link
AU (1) AU6465798A (en)
WO (1) WO1998040748A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI980099A1 (en) * 1998-04-27 1999-10-27 Univ Firenze DIAGNOSTIC METHOD FOR ALGIC PATHOLOGIES
AU2001233954A1 (en) * 2000-02-24 2001-09-03 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of schizophrenia
JP3507884B2 (en) * 2000-03-07 2004-03-15 新潟大学長 Objective diagnosis of schizophrenia using gene expression as an index
US20020164668A1 (en) * 2000-04-03 2002-11-07 Durham L. Kathryn Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
SG121733A1 (en) * 2001-10-03 2006-05-26 Pfizer Prod Inc Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
EP1571970B1 (en) 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
ES2572454T3 (en) 2003-05-15 2016-05-31 Ampio Pharmaceuticals Inc Treatment of diseases mediated by T lymphocytes
CN1300588C (en) * 2005-02-28 2007-02-14 上海交通大学 Method for acquiring plasma specific protein for schizophrenia diagnosis and use thereof
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc METHODS AND THERAPEUTIC COMPOUNDS
GB0915736D0 (en) * 2009-09-09 2009-10-07 Cambridge Entpr Ltd Biomarkers
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
EA028343B1 (en) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Treatment of degenerative joint disease
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP2771007B1 (en) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
MX2015010937A (en) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same.
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US10900980B2 (en) 2015-05-18 2021-01-26 Georgetown University Metabolic biomarkers for memory loss
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US10900977B2 (en) 2015-10-16 2021-01-26 Georgetown University Protein biomarkers for memory loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587091T2 (en) * 1984-11-13 1993-06-03 Esa Inc DEVELOPMENT METHOD FOR DRUG TREATMENT MEDICINES.
US4874694A (en) * 1987-04-07 1989-10-17 The Rockefeller University Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders
JP3221610B2 (en) * 1991-01-18 2001-10-22 エイサ・インコーポレイテツド Methods for detecting or categorizing disorders from biochemical profiles
WO1995005604A2 (en) * 1993-08-13 1995-02-23 Molecular Geriatrics Corporation Methods for the diagnosis of alzheimer's disease
EP0760098A4 (en) * 1994-06-09 1997-07-16 Univ Bar Ilan Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions

Also Published As

Publication number Publication date
WO1998040748A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
AU6465798A (en) Diagnosing neurologic disorders
AU5879198A (en) Vehicle monitor
AU5879098A (en) Vehicle monitor
AU1709299A (en) Mixer-injectors
AU6598798A (en) Resorcinyl-triazines
AU4578297A (en) New combination
AU1027499A (en) 32P-polyphosphazene
AU7966098A (en) Hm74a receptor
AU7474198A (en) Dispenser-applicator assembly
AU6827898A (en) Detergent-package combination
AU9066598A (en) Substituted 4-benzoyl-pyrazoles
AU5272198A (en) EMP-charge-eliminator
AU2752897A (en) Formazan-based immunoassay
AU9635298A (en) Fastening device
AU4322497A (en) Car
AU2954897A (en) Beta-lactams
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AU6185898A (en) Clavaspirins
AU5888698A (en) Refining element
AU7761998A (en) Korrosionsschutzanstrichstoff
AU1040999A (en) Securing mechanism
AU6090898A (en) Substituted 4-benzoyl-pyrazoles
AU8547698A (en) Vehicle
AU9469798A (en) Solar-collecting assembly